相关实验视频

Updated: Jun 24, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

从豆蛋白化物中分泌GLP-1的虚拟选,通过载体1 (PepT1) 激活的基于分子对接

Mingkai Zhang¹, Ling Zhu¹, Hui Zhang¹

¹National Engineering Research Center for Functional Food, Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China.

Journal of agricultural and food chemistry

|June 7, 2024

概括

研究人员发现了两种新的GLP-1分泌,FLR和LRW,来自使用peptidomics和分子对接的豆蛋白水解剂. 这种方法有效地选通过载体1 (PepT1) 调节葡萄糖稳态的.

科学领域:

营养生物化学营养生物化学
分子生物学分子生物学
酸科学是一种科学.

背景情况:

饮食中的蛋白质通过肠道蛋白质感应影响葡萄糖稳定,刺激葡萄糖类1 (GLP-1) 的分泌.
从饮食蛋白质中识别GLP-1分泌是具有挑战性的,因为已知的数量有限,传统方法繁重.

研究的目的:

使用集成的基和分子对接方法,快速识别从豆蛋白化物 (PPH) 中分泌GLP-1.
调查载体1 (PepT1) 在中介PPHs的GLP-1分泌作用中的作用.

主要方法:

虚拟选PPHs使用peptidomic分析识别潜在的.
分子对接模拟以评估已识别的与载体1 (PepT1) 的相互作用.
在NCI-H716细胞中使用PPH和已识别的,有或没有PepT1抗体,对GLP-1分泌的体外验证.

主要成果:

豆蛋白水解剂显著刺激了GLP-1分泌,这种效果取决于PepT1的激活.
通过基于PepT1的分子对接,从PPH中的307个三中鉴定出两种GLP-1分泌,FLR和LRW.
FLR和LRW显著增加了GLP-1水平,以剂量依赖的方式,分子对接揭示了与PepT1活性位点的关键相互作用.

结论:

结合peptidomics和基于PepT1激活的分子对接的结合方法是识别GLP-1分泌的高效策略.
已识别的类FLR和LRW代表了调节葡萄糖平衡的潜在功能成分.
这项研究为从饮食蛋白质中发现生物活性的新平台,用于代谢健康应用.

关键词:

这就是GLP-1.在PepT1中,PepT1是PepT1.分子对接的分子对接.豆酸是豆酸中的一种.虚拟选虚拟选虚拟选

更多相关视频

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...